Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of
Trial also met primary endpoint in first study population as announced September 2022 - The Company plans to work with the FDA to design a Phase 3 program to begin in 2023, ahead of expectations - Horizon
As war rages in Ukraine and inflation impacts the economy, financial institutions in the UK expect the subsequent economic downturn to drive a rise in financial crime. LONDON, Jan. 18,
Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
The Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study Oakville, Ontario--(Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"